Carrying the APOE ɛ4 allele is the strongest genetic risk factor for developing Alzheimer's
disease. The goal of this project is to identify whether carrying the APOE ɛ4 allele is
associated with reduced delivery of DHA to the brain. This information will help us identify
the target population that could benefit from DHA supplementation to prevent cognitive
decline.
Phase:
Phase 2
Details
Lead Sponsor:
University of Southern California
Collaborators:
Alzheimer's Drug Discovery Foundation Huntington Medical Research Institutes National Institute on Aging (NIA)